Neural Therapeutics Inc.
0.00
USD
0.00
(0.00%)
ISIN
CA64134N2032
CUSIP
64134N203
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
CAD
•
in mil. unless spec.Working Capital
CAD
•
in mil. unless spec.Growth Rates
CAD
•
in mil. unless spec.Quarterly Revenue
CAD
•
in mil. unless spec.Quarterly Earnings Per Share
CAD
•
in mil. unless spec.Quarterly Dividends Per Share
CAD
•
in mil. unless spec.Company Description
- Sector
- Health technology
- Industry
- Pharmaceuticals: other
- Address
- Toronto Canada
- IPO Date
- Mar 17, 2025
- Website
- neuraltherapeutics.ca
- Similar Companies
- Business
- Neural Therapeutics Inc. is a clinical-stage ethnobotanical drug-discovery and biotechnology company focused on researching, developing, and commercializing plant-based pharmaceutical therapies derived from ethnomedicinal species for the treatment of mental health and central nervous system disorders. Founded in 2022 and headquartered in Toronto, Canada, the company operates within the life sciences and biopharmaceutical sectors, targeting indications such as substance use disorders, alcohol dependence, treatment-resistant depression, anxiety, and neuroinflammatory conditions. Neural Therapeutics focuses its core development programs on mescaline and related alkaloid compounds derived from the San Pedro cactus (Echinopsis pachanoi) and traditional South American botanical preparations. The company offers a comprehensive pipeline of research and therapeutic assets, comprising proprietary botanical drug formulations and phenethylamine-based chemical entities; standardized pharmaceutical-grade active pharmaceutical ingredients (APIs) and botanical extracts; preclinical developmental assets evaluating neurobehavioral efficacy, pharmacology, and toxicology; and intellectual property assets covering proprietary botanical extraction, purification, stabilization, and delivery technologies. Geographically, the company maintains corporate and operational management in Canada while conducting botanical sourcing, agricultural cultivation, and pharmacological research in Peru through collaborative partnerships with local academic and research institutions, including the Universidad Nacional Mayor de San Marcos. In recent developments, the company completed the listing of its common shares on the Canadian Securities Exchange under the ticker symbol NURL; established key collaborative research and development agreements in Peru to advance ethnobotanical drug discovery; advanced preclinical pharmacology studies for its lead mescaline-based candidate targeting substance use disorders; completed equity financings through non-brokered private placements to support pipeline expansion; and strengthened its scientific advisory board and corporate governance to accelerate intellectual property prosecution and regulatory development pathways.